BioPharma Resources

Drug Trial Radar · NCT07490496

Phase 3 Bunionectomy Study

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CPL-01 in the Management of Postoperative Pain After Unilateral Distal First Metatarsal Bunionectomy With Osteotomy

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Mar 1, 2027

Primary completion

Jun 30, 2027

Study completion Aug 30, 2027

Sponsor

Lead sponsor
Cali Pharmaceuticals LLCIndustry
Sponsor type
Industry
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with a bunion will have that repaired and then pain and rescue medicine use will be evaluated.

Conditions

  • Postoperative Pain
  • Bunion

Interventions

  • CPL-01Drug

    Administration by the Surgeon during the operation

  • saline placeboDrug

    Administration by the Surgeon during the operation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Postoperative Pain with activityTime frame: 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CenExel

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.